Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine.

Molecular pharmacology - 1 Apr 2001

Karpf A R, Moore B C, Ririe T O, Jones D A

Abstract excerpt

Transcriptional silencing of tumor suppressor genes by DNA methylation occurs in cancer cell lines and in human tumors. This has led to the pursuit of DNA methyltransferase inhibition as a drug target. 5-Aza-2'-deoxycytidine [5-aza-CdR (decitabine)], a potent inhibitor of DNA methyltransferase, i...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Azacitidine
Share to Cyclin-Dependent Kinase Inhibitor p21

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclins

Share to Decitabine

Share to DNA Modification Methylases

Share to G1 Phase

Share to HT29 Cells

Source

Identifiers

PMID: 11259619

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026. Prepared record publication-11259619-2026-08-31.1. Manifest publication-graph-cohort-2026-08-31.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 31 Aug 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine.PMID 11259619Read ↗

5-Aza-2′-deoxycytidine Activates the p53/p21Waf1/Cip1 Pathway to Inhibit Cell ProliferationSemantic proximity Read ↗

p53 status determines the epigenetic response to demethylating agents Azacitidine and DecitabineSemantic proximity Read ↗

Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine).Semantic proximity Read ↗

Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine.Semantic proximity Read ↗

Inhibition of DNA methyltransferase induces G2 cell cycle arrest and apoptosis in human colorectal cancer cells <i>via</i> inhibition of JAK2/STAT3/STAT5 signallingSemantic proximity Read ↗

5‐Aza‐2′‐deoxycytidine induces p21<sup>WAF</sup> expression by demethylation of p73 leading to p53‐independent apoptosis in myeloid leukemiaSemantic proximity Read ↗

Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cellsSemantic proximity Read ↗

A Defect in the p53 Response Pathway Induced by de Novo Purine Synthesis InhibitionSemantic proximity Read ↗

Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function.Semantic proximity Read ↗

Selected drugs that inhibit DNA methylation can preferentially kill p53 deficient cells.Semantic proximity Read ↗

Disruption of p53 in human cancer cells alters the responses to therapeutic agentsSemantic proximity Read ↗

5-aza-2'-deoxycytidine-induced genome rearrangements are mediated by DNMT1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.